Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 26 publications
Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms.
Journal: Haematologica
Published: April 09, 2026
Ropeginterferon alfa-2b-njft treatment in essential thrombocythemia across different driver mutations: results from a North American, single-arm, multicentre study (EXCEED-ET).
Journal: Lancet regional health. Americas
Published: March 25, 2026
Avapritinib achieves long-term disease control with favorable safety in patients with indolent systemic mastocytosis over 3 years.
Journal: The Journal of allergy and clinical immunology
Published: December 16, 2025
Anaphylaxis events in the PIONEER study of avapritinib in indolent systemic mastocytosis.
Journal: The World Allergy Organization journal
Published: May 29, 2025
Avapritinib improves cutaneous involvement in patients with indolent systemic mastocytosis: Results from the randomized, phase 2, interventional PIONEER study.
Journal: Journal of the American Academy of Dermatology
Published: March 24, 2025
A multicenter study to assess efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in patients with essential thrombocythemia in the US and Canada: EXCEED-ET trial.
Journal: Frontiers in medicine
Published: January 11, 2025
ECLIPSE-PV: A Randomized, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Two Dosing Regimens of Ropeginterferon Alfa-2b-Njft in Polycythemia Vera.
Journal: Acta haematologica
Published: December 16, 2024
Avapritinib versus Placebo in Indolent Systemic Mastocytosis.
Journal: NEJM evidence
Published: February 06, 2024
Correction: Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Journal: Bone marrow transplantation
Published: January 26, 2024
Upfront allogeneic transplantation versus JAK inhibitor therapy for patients with myelofibrosis: a North American collaborative study.
Journal: Bone marrow transplantation
Published: August 24, 2023
Clinical Features and Long-Term Outcomes of a Pan-Canadian Cohort of Adolescents and Young Adults with Myeloproliferative Neoplasms: A Canadian MPN Group Study.
Journal: Leukemia
Published: August 17, 2023
Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
Journal: Leukemia research
Published: June 22, 2023
Last Updated: 09/26/2026